Top

Published in:

01-06-2015 | Research Article

SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation

Authors: Sujuan Yan, Yan Deng, Yong Qiang, Qinghua Xi, Rong Liu, Shuyun Yang, Jian Liu, Chunhui Tang, Jianxin Zhong, Yingying Wang

Published in: Tumor Biology | Issue 6/2015

Abstract

SYF2 is reported to be as a cell cycle regulator at the G1/S transition and encodes a nuclear protein that interacts with cyclin-D-type binding protein 1. In our study, we investigated the role of SYF2 in human epithelial ovarian cancer (EOC) progression. Western blot and immunohistochemistry analysis displayed that SYF2 was overexpressed in EOC tissues and EOC cell lines. In addition, the immunoreactivity of SYF2 was positively correlated with tumor grade and Ki-67 expression. In vitro, serum starvation-refeeding experiment and SYF2-siRNA transfection assay demonstrated that the expression of SYF2 was promoted in the proliferative progression of EOC cells, while knockdown of SYF2 expression decreased and inhibited cell growth rate of EOC cells. With all the results, we support that SYF2 might contribute to EOC progression via modulation of proliferation in EOC cells and would provide a novel therapeutic target of human EOC.

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81. doi:10.1016/j.ejca.2009.12.014.CrossRefPubMed

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. doi:10.3322/caac.20006.CrossRefPubMed

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.CrossRefPubMed

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.20138.CrossRefPubMed

Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719–25. doi:10.1038/nrc3144.CrossRefPubMedPubMedCentral

Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol. 2003;1:66. doi:10.1186/1477-7827-1-66.CrossRefPubMedPubMedCentral

Chu PC, Yang YC, Lu YT, Chen HT, Yu LC, Chang MS. Silencing of p29 affects DNA damage responses with UV irradiation. Cancer Res. 2006;66(17):8484–91. doi:10.1158/0008-5472.CAN-05-3229.CrossRefPubMed

Chang MS, Chang CL, Huang CJ, Yang YC. p29, a novel GCIP-interacting protein, localizes in the nucleus. Biochem Biophys Res Commun. 2000;279(2):732–7. doi:10.1006/bbrc.2000.3992.CrossRefPubMed

Dahan O, Kupiec M. Mutations in genes of Saccharomyces cerevisiae encoding pre-mRNA splicing factors cause cell cycle arrest through activation of the spindle checkpoint. Nucleic Acids Res. 2002;30(20):4361–70.CrossRefPubMedPubMedCentral

10.

Chen CH, Chu PC, Lee L, Lien HW, Lin TL, Fan CC, et al. Disruption of murine mp29/Syf2/Ntc31 gene results in embryonic lethality with aberrant checkpoint response. PLoS One. 2012;7(3):e33538. doi:10.1371/journal.pone.0033538.CrossRefPubMedPubMedCentral

11.

Vincent K, Wang Q, Jay S, Hobbs K, Rymond BC. Genetic interactions with CLF1 identify additional pre-mRNA splicing factors and a link between activators of yeast vesicular transport and splicing. Genetics. 2003;164(3):895–907.PubMedPubMedCentral

12.

Chu PC, Wang TY, Lu YT, Chou CK, Yang YC, Chang MS. Involvement of p29 in DNA damage responses and Fanconi anemia pathway. Carcinogenesis. 2009;30(10):1710–6. doi:10.1093/carcin/bgp204.CrossRefPubMed

13.

Ma W, Stafford LJ, Li D, Luo J, Li X, Ning G, et al. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis. J Cell Biochem. 2007;100(6):1376–86. doi:10.1002/jcb.21140.CrossRefPubMed

14.

Cui X, Liu Y, Wan C, Lu C, Cai J, He S, et al. Decreased expression of SERPINB1 correlates with tumor invasion and poor prognosis in hepatocellular carcinoma. J Mol Histol. 2014;45(1):59–68. doi:10.1007/s10735-013-9529-0.CrossRefPubMed

15.

Song W, Hu L, Li W, Wang G, Li Y, Yan L, et al. Oncogenic Fli-1 is a potential prognostic marker for the progression of epithelial ovarian cancer. BMC Cancer. 2014;14(1):424. doi:10.1186/1471-2407-14-424.CrossRefPubMedPubMedCentral

16.

Zhu J, Ji L, Zhang J, Yang L, Guan C, Wang Y, et al. Upregulation of SYF2 in esophageal squamous cell carcinoma promotes tumor cell proliferation and predicts poor prognosis. Tumour Biol J Int Soc Oncodev Biol Med. 2014. doi:10.1007/s13277-014-2305-2.

17.

Guo J, Yang L, Huang J, Liu X, Qiu X, Tao T, et al. Knocking down the expression of SYF2 inhibits the proliferation of glioma cells. Med Oncol. 2014;31(8):101. doi:10.1007/s12032-014-0101-x.CrossRefPubMed

18.

Xu W, Cao M, Zheng H, Tan X, Li L, Cui G, et al. Upregulation of SYF2 is associated with neuronal apoptosis caused by reactive astrogliosis to neuroinflammation. J Neurosci Res. 2014;92(3):318–28. doi:10.1002/jnr.23312.CrossRefPubMed

19.

Chang MS, Chen CY, Yeh HI, Fan CC, Huang CJ, Yang YC. Cloning, expression, and genomic organization of mouse mp29 gene. Biochem Biophys Res Commun. 2002;299(2):241–6.CrossRefPubMed

20.

Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem. 1989;264(23):13856–64.PubMed

21.

Pisani P, Parkin DM, Bray F, Ferlay J. Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18-29 (1999). International journal of cancer Journal international du cancer. 1999;83(6):870-3.

22.

Aris A. Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res. 2010;3:2. doi:10.1186/1757-2215-3-2.CrossRefPubMedPubMedCentral

23.

Cho H, Shin HY, Kim S, Kim JS, Chung JY, Chung EJ, et al. The role of S100A14 in epithelial ovarian tumors. Oncotarget. 2014;5(11):3482–96.CrossRefPubMedPubMedCentral

24.

Ben-Yehuda S, Dix I, Russell CS, McGarvey M, Beggs JD, Kupiec M. Genetic and physical interactions between factors involved in both cell cycle progression and pre-mRNA splicing in Saccharomyces cerevisiae. Genetics. 2000;156(4):1503–17.PubMedPubMedCentral

Title: SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation
Authors: Sujuan Yan
Yan Deng
Yong Qiang
Qinghua Xi
Rong Liu
Shuyun Yang
Jian Liu
Chunhui Tang
Jianxin Zhong
Yingying Wang
Publication date: 01-06-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3111-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

New approaches for cancer immunotherapy

Divergent expression patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and normal tissues

Glucose-regulated protein 78 mediates the therapeutic efficacy of 17-DMAG in colon cancer cells

Protein kinase D2 silencing reduced motility of doxorubicin-resistant MCF7 cells

Decreased expression of microRNA-107 predicts poorer prognosis in glioma

MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer